BeOne Medicines stock rises after positive trial results for cancer treatment

Investing.com -- BeOne Medicines AG (NASDAQ:ONC) stock rose 4.2% on Monday after the global oncology company announced positive top-line results from a Phase 3 trial evaluating its HER2-targeted bispecific antibody ZIIHERA in combination with chemotherapy for gastroesophageal cancer.

The HERIZON-GEA-01 trial showed that ZIIHERA (zanidatamab) plus chemotherapy, with or without the PD-1 inhibitor TEVIMBRA (tislelizumab), demonstrated "clinically meaningful and highly statistically significant improvements" in progression-free survival compared to the control arm of trastuzumab plus chemotherapy.

Additionally, the ZIIHERA plus TEVIMBRA and chemotherapy combination showed statistically significant improvements in overall survival. The ZIIHERA plus chemotherapy arm also demonstrated a "clinically meaningful effect with a strong trend toward statistical significance" for overall survival compared to the control arm.

The trial is ongoing with an additional planned overall survival interim analysis for ZIIHERA plus chemotherapy expected in mid-2026.

"These results represent meaningful progress for a patient community in urgent need of new treatment options," said Mark Lanasa, Chief Medical Officer for Solid Tumors at BeOne. "With the high incidence of GEA across many regions where we hold rights to ZIIHERA, we have the opportunity to deliver a major advancement for patients in an area of high unmet need."

The company reported that the safety profile of the treatment combinations was generally consistent with the known safety profiles of each agent, with no new safety signals observed.

BeOne plans to submit the data for presentation at a major medical meeting in the first quarter of 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.